drugset
drugset / Trial / NCT00389519

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

NCT00389519 ↗

Phase 3 Terminated 422 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the blood pressure lowering effects of ramipril, an FDA-approved drug for the treatment of hypertension in adults, in children and adolescents aged 6 to 16 years with hypertension.

Timeline

Start
2006-10
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramipril Small molecule 0.3125 mg Oral
Subject Ramipril Small molecule 0.625 mg Oral
Subject Ramipril Small molecule 1.25 mg Oral
Subject Ramipril Small molecule 2.5 mg Oral
Subject Ramipril Small molecule 5 mg Oral
Subject Ramipril Small molecule 10 mg Oral
Subject Ramipril Small molecule 20 mg Oral

Indications

hypertensive disorder